Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T06:21:01.632Z Has data issue: false hasContentIssue false
  • English
  • Français

Emergence of Daptomycin-Resistant VRE: Experience of a Single Institution

Part of: BARRY FARR AWARD RECIPIENTS

Published online by Cambridge University Press:  02 January 2015

Mini Kamboj ,
Nina Cohen ,
Kathleen Gilhuley ,
N. Esther Babady ,
Susan K. Seo  and
Kent A. Sepkowitz
Mini Kamboj*
Affiliation:
Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065
Nina Cohen
Affiliation:
Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065
Kathleen Gilhuley
Affiliation:
Microbiology Service, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, New York 10065
N. Esther Babady
Affiliation:
Microbiology Service, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, New York 10065
Susan K. Seo
Affiliation:
Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065
Kent A. Sepkowitz
Affiliation:
Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065
*
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 9, New York, NY 10065 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Recent surveillance from US hospitals shows that more than 99.5% of vancomycin-resistant enterococci (VRE) isolates remain susceptible to daptomycin. This report describes emergence of daptomycin-resistant VRE at a major cancer center. The percentage of patients with daptomycin-resistant VRE bacteremia increased from 3.4% in 2007 to 15.2% in 2009 (P = .03). Without susceptibility data, empiric daptomycin therapy for VRE infections should be used with caution.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 32 , Issue 4 , April 2011 , pp. 391 - 394
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. National Nosocomial Infections Surveillance (NNIS) System. NNIS report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32(8):470–485.Google Scholar
2. DiazGranados, CA, Zimmer, SM, Klein, M, Jernigan, JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41(3):327–333.Google Scholar
3. Sader, HS, Jones, RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009;65(2):158–162.Google Scholar
4. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing—Twentieth Information Supplement. Wayne, PA: CLSI; 2010. CLSI document M100-S20.Google Scholar
5. Tenover, FC, Arbeit, RD, Goering, RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33(9):2233–2239.Google Scholar
6. Silverman, JA, Oliver, N, Andrew, T, Li, T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45(6):1799–1802.Google Scholar
7. Montero, CI, Stock, F, Murray, PR. Mechanisms of resistance to daptomycin in Enterococcus faecium . Antimicrob Agents Chemother 2008;52(3):1167–1170.Google Scholar
8. Lesho, EP, Wortmann, GW, Craft, D, Moran, KA. De novo daptomycin nonsusceptibility in a clinical isolate. J Clin Microbiol 2006;44(2):673.Google Scholar
9. Fraher, MH, Corcoran, GD, Creagh, S, Feeney, E. Daptomycin-resistant Enterococcus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect 2007;65(4):376–378.Google Scholar
10. Lewis, JS II, Owens, A, Cadena, J, Sabol, K, Patterson, JE, Jorgensen, JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;49(4):1664–1665.Google Scholar
11. Long, JK, Choueiri, TK, Hall, GS, Avery, RK, Sekeres, MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 2005;80(9):1215–1216.Google Scholar